# Crystal Pharmatech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/crystal-pharmatech

- Industry: Pharmaceuticals
- Headquarters: Suzhou, China
- Website: www.crystalpharmatech.com
- Total disclosed funding: $15M
- Latest round: Series B (Dec 25, 2018)
- Investors on record: 3

## About

Crystal Pharmatech is a contract development and manufacturing organization (CDMO) and contract research organization (CRO) that provides tailored solutions for the pharmaceutical industry, focusing on active pharmaceutical ingredient research and formulation development.Founded in 2010 in Suzhou, China, Crystal Pharmatech operates as a CDMO and CRO, catering to the pharmaceutical sector. The company has undergone strategic pivots to enhance its service offerings and has completed two deals, the most recent on December 25, 2018, when it raised CNY 100 million in a Series B funding round led by Shiyu Capital, alongside Cowin Capital and Oriza Holdings. The company was co-founded by Yanfeng Zhang, who has a history in the pharmaceutical industry. Crystal Pharmatech serves clients globally, including eight of the top ten multinational pharmaceutical firms.Crystal Pharmatech specializes in a comprehensive range of CDMO and CRO services tailored for the pharmaceutical sector. Their offerings include active pharmaceutical ingredient solid-state research, crystallization, preformulation, formulation development, and clinical supply manufacturing, addressing critical challenges faced by drug developers from early-stage formulation to commercial manufacturing. The company has facilitated the development of over 2,000 drug molecules for clients across North America, Europe, and Asia.Crystal Pharmatech generates revenue through B2B transactions and direct service agreements with pharmaceutical and biotech companies. These are typically project-based contracts for specific formulation and manufacturing services, reflecting a commitment to quality and efficiency. Revenue is derived from fee-for-service arrangements tailored to the complexity and duration of each project, supporting clients from preclinical phases to commercialization.In December 2018, Crystal Pharmatech raised CNY 100 million in Series B funding to support future growth strategies. The company plans to leverage this funding to expand its service offerings and enhance its capabilities in drug development. The firm is also looking to penetrate new markets, particularly focusing on expanding its presence in emerging regions over the next few years, thereby increasing operational reach and service capacity.

## Funding rounds

- Series B, Dec 25, 2018, $15M — Oriza Holdings, Cowin Capital, Shiyu Capital

## Investors

- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series B
- Cowin Capital (https://capitalatlas.ai/funds/cowin-capital) — Series B
- Shiyu Capital (https://capitalatlas.ai/funds/shiyu-capital) — Series B